VYVGART (efgartigimod) by Argenx was launched in January 2022 and has pocketed sales beyond estimates in its first quarter (1Q22). Argenx is also developing SC efgartigimod in collaboration with subcutaneous delivery systems' player, Halozyme, to treat gMG patients. The company announced a positive data readout of its Phase III studies in 2H22. It also announced plans to file BLA by the end of 2022. Argenx also plans to commercialize the asset with a different brand name, as it plans to take a second bite at the generalized myasthenia gravis treatment market. The asset is anticipated to achieve high generalized myasthenia gravis market penetration owing to its long-acting nature and favorable ease of administration. It is expected to enter the US generalized myasthenia gravis treatment market by 2023.